Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,511 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 |
| clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05630131 | ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy | completed | — | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07251946 | Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer | completed | — | 316 | Lian YangOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05696444 | Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) | active not recruiting | N/A | 144 | Medtronic - MITGINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04412070 | Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients(ALU) | terminated | — | 20 | Hopital FochOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06537960 | Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers(TARDITEP) | recruiting | N/A | 66 | Hopital FochOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07037589 | Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?(BLUSH) | recruiting | — | 300 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07225205 | Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy | recruiting | N/A | 130 | Johns Hopkins UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03837821 | (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer(CLONEVO) | active not recruiting | Early Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04533672 | Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making(SBCT) | completed | N/A | 186 | University of ZurichOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05792722 | Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy | recruiting | N/A | 70 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06525571 | Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | recruiting | Phase 3 | 200 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer(GEMDOCE) | active not recruiting | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06190197 | Prophylactic Antibiotics in Cystectomy With Diversion | recruiting | Early Phase 1 | 120 | University of MinnesotaOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06397040 | The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical Cystectomy(WATCH) | completed | N/A | 38 | University of PittsburghOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03747419 | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06396533 | Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)(INSITE) | recruiting | — | 92 | Fox Chase Cancer CenterOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer(GETUGV04) | terminated | N/A | 69 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05649306 | Gender Related Coping and Survivorship for Genitourinary Cancers | recruiting | — | 80 | Johns Hopkins UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06427824 | Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy | recruiting | N/A | 85 | University of ChicagoOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05783271 | Validity of Parametric MRI Using VIRADS(metricMRI) | recruiting | N/A | 58 | Assiut UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204132 | Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy | recruiting | N/A | 180 | Changhai HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204301 | Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study(Flexi-comfort) | not yet recruiting | N/A | 378 | Western University, CanadaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204496 | A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer(γδ-T-BLADDER) | not yet recruiting | — | 20 | Shanghai 10th People's HospitalOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT01563796 | Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer | terminated | — | 1,115 | Medical Diagnostic Laboratories, LLCINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06157814 | Mobile Ostomates Resources for Patients and Caregivers(MORE) | completed | N/A | 26 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07187063 | Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer | recruiting | N/A | 56 | Lahey ClinicOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05739071 | JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer | enrolling by invitation | N/A | 100 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07165236 | Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor | recruiting | — | 42 | Osijek University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2025source: clinicaltrials